María J. Ribal

1 ta ish

Hospital Clínic de Barcelona

1. A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma.

   Magnus Lindskog, Anna Laurell, Anders Kjellman +17

   Maqola20202 iqtibos

   ABIABI:AkademIndex/2026.other.586483